Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its only real competitor in the field, Novo Nordisk.However, Lilly is not taking its foot off the pedal; it just made a move that could improve its already solid position in this space. Let's figure out whether this new development makes the company's shares even more attractive.There is no questioning the efficacy of Eli Lilly's Zepbound, its leading weight-management medicine. The therapy posted excellent results in clinical trials, and has now been in use in real-world settings long enough to confirm its clinical profile.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool